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the history of otitis media and carcinoma of the
cheek: a case report”
Khabti AlmuhannaAbstract
Background: Neuroendocrine adenomas of the middle ear are rare benign tumors deriving from middle ear
mucosal cell with both neuroendocrine and epithelial properties. Approximately one hundred cases have been
reported in the literature. Here we report a patient with neuroendocrine adenoma of the middle ear with the
history of otitis media; the patient earlier had received radiotherapy for the treatment of basal cell carcinoma.
Case presentation: A 49- year- old Saudi man presented with a progressive hearing loss and fullness in the left ear
with the history of otitis media for which he had undergone myringotomy and ventilating tubes insertion. Earlier at
the age of 45 years this patient was given radiotherapy for the treatment of basal cell carcinoma in his cheek. The
otoscopy showed a protruded external ear mass obscuring the tympanic membrane. Microscopy and histological
examination suggested an endocrine adenoma of the middle ear. The computerized tomography scan of the
temporal bone showed an extensive soft tissue mass without any osteolysis. Histological and immunohistochemical
examination following surgical excision confirmed the diagnosis of neuroendocrine adenoma of the middle ear.
Conclusion: A rare case of neuroendocrine adenoma of the middle ear with earlier history of otitis media and
carcinoma of the cheek is presented here. Surgical excision of mass resulted in uneventful recovery. Although the
etiologic factors leading to the disease is far from clear, the role of radiotherapy given for the treatment of basal
cell carcinoma may not be ruled out.
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Benign glandular neoplasms arising in the middle ear
cavity are quite rare. Only around one hundred cases
have been reported in the literature since they were first
described by Derlacki [1] in 1976. It is believed that
different names given to these lesions including cermi-
noma, ceruminous adenoma, monomorphic adenoma,
adenocarcinoma and carcinoid tumor [2] represents the
same tumor with the different degree of neuroendocrine
differentiation, hence these lesions are now unified [3]
under the name “neuroendocrine adenoma of the middle
ear (NAME).” As the clinical presentation, otoscopic ap-
pearance and radiological findings of NAME are non-Correspondence: kmohan13@hotmail.com
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reproduction in any medium, provided the orspecific [4-7] a definitive diagnosis is based on histo-
logical and immunohistochemical findings [5].
Here, we report a case of a 49- year- old Saudi man pre-
sented with progressive hearing loss and fullness of left
ear with the history of recurrent otitis media with effusion
for which had undergone myrigotomy and insertion of
ventilating tube. This patient had also undergone radio-
therapy for the treatment of basal cell carcinoma of cheek
at the age of 45 years. To the best of our knowledge, this
is the first report of such a case from Saudi Arabia.
Case presentation
A 49-year-old Saudi man consulted for an abnormal sen-
sation of fullness in the left ear and progressive hearing
loss without discharge. The patient had a history of hear-
ing loss in the same left ear more than 20 years ago and
was diagnosed as otitis media with effusion (OME). The
patient had undergone left ear myringotomy and insertiontd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 2 Computed tomography scan of inner part of left
external auditory canal. An irregular soft tissue lesion seen in the
inner part of the left external auditory canal just lateral to the tympanic
membrane, soft tissue density is also seen implicating the Prussak’s
space, epitympanum, mesotympanum and hypotympanum.
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years ago this patient also received radiotherapy for the
treatment of basal cell carcinoma of the cheek.
The otologic examination of left ear showed polypoidal
mass in the posterior wall of the left external auditory
canal that occluded the tympanic membrane (Figure 1).
The facial nerve function was normal. Audiometric evalu-
ation showed moderate conductive hearing loss. Computed
tomography (CT) scan of the temporal bones (Figure 2) re-
vealed an irregular soft tissue lesion in the inner part of
the left external auditory canal just lateral to the tympanic
membrane. No bony erosive changes were detected in the
external auditory canal. The left mastoid air cells were
opacified. A soft tissue density mass occupied the left mid-
dle ear cavity implicating the Prussak’s space, epitympa-
num, mesotympanum and hypotympanum. The mastoid
ad antrum and mastoid antrum were also opacified by the
soft tissue lesion. However, no evidence of erosive changes
was found in the scutum or ossicular chain. The patient
underwent excision of the left middle ear mass including
the radical mastoidectomy due to extensive nature of
tumor and to avoid future recurrence.
Microscopic examination of excised tumor revealed
the presence of cuboidal and plasmacytoid cells arranged
in solid sheets and in a trabecular patterns (Figure 3).
Focal areas showed infiltrative pattern. The immunocyto-
chemistry was positive for immunostains pancytokeratin
(CKAE1/3), neuroendocrine markers including synapto-
physin and chromogranin (Figure 4). However, they
were negative for other tumor marker immunostains
such as desmin, S100 Proteins, cytokeratin 20 (CK20),
cytokeratin 7 (CK7), thyroid transcription factor 1 (TTF1)
and tumor protein (P63) without any atypical cells
(Figure 5). Based on histological and immunohistochemicalFigure 1 Otoscopic view scan of left external auditory canal.
Polypoidal mass in the posterior wall of the left external auditory
canal that was occluding the tympanic membrane.findings diagnosis of neuroendocrine adenoma of the middle
ear was confirmed. The post-operative period of 10 months
was uneventful with no sign of recurrence.
Discussion
Neuroendocrine adenomas of the middle ear are rare
glandular lesion which account for less than 2% of all ear
tumors. The mean age of NAME cases is around 45 years
with no sex predominance [2]. Due to the slow growth
rate and rarity of these tumors, the diagnosis of these tu-
mors is often delayed [4]. The clinical signs, otoscopic
examination and radiological findings of NAME are quiteFigure 3 Microscopic examination of tumor cells. Tumor
composed of glands and trabecule, uniform cuboidal cells, abundant
cytoplasm, eccentrically nuclei, chromatin display a “salt-and-pepper”
pattern, no mitotic activity or necrosis.
Figure 4 Immunohistochemistry (positive for): Pancytokeratin
CKAE l/3, Neuroendocrine markers (synaptophysin and
chromogranin) and Vimentin.
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The patient described in this case study complained a
sense of fullness and progressive hearing loss in left ear
over several years. The otologic examination showed the
presence of polypoidal mass in the posterior wall of exter-
nal auditory canal which protruded and occluded tym-
panic membrane. Our case is similar to several reported
cases who also showed various degree of hearing loss in
NAME patients [8,9], however majority of cases of NAME
had symptoms of otalgia, otorrhea, dizziness and tinnitus
[1,4,5,8-10], whereas some of the reported cases were to-
tally asymptomatic [1,11]. Moreover most of the reported
cases had intact tympanic membrane displaced medically
by a retro tympanic mass [1,8,11]. Unlike our case facial
paralysis due to compression of nerve (without inva-
sion of lesion) was reported in several earlier cases [5].
The audiometric evaluation of our patient showed a mod-
erate conductive hearing loss. Imaging of our patientFigure 5 Immunohistochemistry (negative for): S100, Desmin,
CK20/CK7, TTF1 and P63.showed irregular soft tissue lesion in the inner part of left
auditory canal just lateral to the tympanic membrane
without any bony erosive change. Earlier radiological stud-
ies on NAME some patients have showed homogenous,
hypodense lesions of temporal bone well limited to the
middle ears [8,12]. The patient in this study underwent a
complete excision of the left middle ear tumor along with
radical mastoidectomy to avoid future recurrence. The
microscopic examination revealed the presence of cuboidal
and plasmacytoid cells arranged in a trabecular patterns.
The immunohistochemistry was positive for neuroendo-
crine markers pancytokeratin, synaptophysin, chromogra-
nin and vimentin immunostains confirming the presence
of NAME.
Surgical excision is the only curative treatment of NAME
[5,8,9,11]. Generally, the treatment consists of complete
surgical excision of tumor along with removal of the ossic-
ular chain, if involved [5,8]. Surgery should be tailored on
the basis of the clinical and radiological findings; however
a generalization of treatment is not advisable. A transcanal
tympanotomy is performed if the lesion is small and con-
fined to the middle ear cleft [11]. On the other hand, if the
lesion fills most of the middle ear, a facial recess approach
mastoidectomy is recommended [9,11]. Torske et al. [5]
reported a recurrence rate of 18% in their series and
underlined the fact that the ossicular chain was left intact
in all their patients [8]. In view of these findings a complete
surgical removal of the neoplasm including encased ossi-
cles, should be the treatment of choice. Moreover, surgical
reconstruction of the tympanic membrane is simultan-
eously performed during the operation. However, in our
case due to extensive disease we left it without reconstruc-
tion. Although the recurrence is rare in cases with initial
complete excision, the patient must be followed closely for
possible recurrence of the disease. No adjuvant treat-
ment was given along with surgical excision as suggested
in earlier reports [8,9]. In our case so far a follow up of
10 months has shown no sign of recurrence. The average
reported interval for the recurrence is 158 months [13].
However the reports about metastases are extremely rare
and even controversial [4,5,7,13]. A regular long term
patient follow-up with otoscopy and audiometry is rec-
ommended. Some authors suggest systematically CT or
magnetic resonance imaging (MRI) examination in order
to detect recurrences [10].
The case present in this report is different from the earl-
ier reported cases due the fact that this patient had a his-
tory of otitis media with effusion for which he had twice
undergone myringotomy. Moreover, four years before the
diagnosis of NAME this patient had received radiotherapy
for the treatment of basal cell carcinoma of cheek. The
risk of cancer from medical radiation has been reported
earlier [14,15]. Hence, a possible role of radiation in the
genesis of NAME may not be ruled out.
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Over all middle ears adenoma with neuroendocrine dif-
ferentiation is uncommon tumor. Surgical excision of
the tumor is the only curative treatment. The pathogen-
esis of these tumors is far from clear. Earlier reports sug-
gest that irradiation enhance the risk of tumors. In our
case the patient had received radiotherapy for the treat-
ment of carcinoma four years prior to the diagnosis of
NAME. Hence, the role of radiotherapy in the etiology of
NAME in this case may not be ruled out.
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